Plenty of moving parts in that announcement and we will never...

Plenty of moving parts in that announcement and we will never know what was holding things up but big picture, acquisition of Access is huge and very smart, so kudos to the Respiri team and the relatively low cost indicates Access believes in the future value of the combined company. In one action you get tremendous upside in revenues for wheezo ( multiple of 3 or more per patient), but now we pick up their cardiovascular, diabetes and obesity patient revenues as well - this must have a major impact on the projected short term financials. Should accelerate timeline to cash flow positive significantly if milestones are met.
Would like to hear more about US based investors and plans around that, not always tapping the Australian shareholders for the SPP although getting in at this level is attractive given what is happening. Not completely sold on new Director, as a long term shareholder remember he was quite critical of Respiri and wheezo vis a vis Resapp and by his own admission that product was a failure in the US. They sold it for pocket money to Pfizer who is doing nothing with it, Respiri and wheezo is a billion dollar + opportunity from here in the right hands, don't want any short term self interest getting in the way.

Once again well done Respiri execute on the plan , deliver the expected vision of this strategy and happy days !!